文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

作者信息

Arevalo-Rodriguez Ingrid, Smailagic Nadja, Roqué I Figuls Marta, Ciapponi Agustín, Sanchez-Perez Erick, Giannakou Antri, Pedraza Olga L, Bonfill Cosp Xavier, Cullum Sarah

机构信息

Division of Research, Fundación Universitaria de Ciencias de la Salud - Hospital San Jose/ Hospital Infantil de San Jose, Carrera 19 Nº 8a - 32, Bogotá D.C., Bogota DC, Colombia, 11001.

出版信息

Cochrane Database Syst Rev. 2015 Mar 5;2015(3):CD010783. doi: 10.1002/14651858.CD010783.pub2.


DOI:10.1002/14651858.CD010783.pub2
PMID:25740785
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6464748/
Abstract

BACKGROUND: Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were estimated to be living with dementia. Some people with mild cognitive impairment (MCI) will progress to dementia but others remain stable or recover full function. There is great interest in finding good predictors of dementia in people with MCI. The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings. OBJECTIVES: To determine the diagnostic accuracy of the MMSE at various thresholds for detecting individuals with baseline MCI who would clinically convert to dementia in general, Alzheimer's disease dementia or other forms of dementia at follow-up. SEARCH METHODS: We searched ALOIS (Cochrane Dementia and Cognitive Improvement Specialized Register of diagnostic and intervention studies (inception to May 2014); MEDLINE (OvidSP) (1946 to May 2014); EMBASE (OvidSP) (1980 to May 2014); BIOSIS (Web of Science) (inception to May 2014); Web of Science Core Collection, including the Conference Proceedings Citation Index (ISI Web of Science) (inception to May 2014); PsycINFO (OvidSP) (inception to May 2014), and LILACS (BIREME) (1982 to May 2014). We also searched specialized sources of diagnostic test accuracy studies and reviews, most recently in May 2014: MEDION (Universities of Maastricht and Leuven, www.mediondatabase.nl), DARE (Database of Abstracts of Reviews of Effects, via the Cochrane Library), HTA Database (Health Technology Assessment Database, via the Cochrane Library), and ARIF (University of Birmingham, UK, www.arif.bham.ac.uk). No language or date restrictions were applied to the electronic searches and methodological filters were not used as a method to restrict the search overall so as to maximize sensitivity. We also checked reference lists of relevant studies and reviews, tracked citations in Scopus and Science Citation Index, used searches of known relevant studies in PubMed to track related articles, and contacted research groups conducting work on MMSE for dementia diagnosis to try to locate possibly relevant but unpublished data. SELECTION CRITERIA: We considered longitudinal studies in which results of the MMSE administered to MCI participants at baseline were obtained and the reference standard was obtained by follow-up over time. We included participants recruited and clinically classified as individuals with MCI under Petersen and revised Petersen criteria, Matthews criteria, or a Clinical Dementia Rating = 0.5. We used acceptable and commonly used reference standards for dementia in general, Alzheimer's dementia, Lewy body dementia, vascular dementia and frontotemporal dementia. DATA COLLECTION AND ANALYSIS: We screened all titles generated by the electronic database searches. Two review authors independently assessed the abstracts of all potentially relevant studies. We assessed the identified full papers for eligibility and extracted data to create two by two tables for dementia in general and other dementias. Two authors independently performed quality assessment using the QUADAS-2 tool. Due to high heterogeneity and scarcity of data, we derived estimates of sensitivity at fixed values of specificity from the model we fitted to produce the summary receiver operating characteristic curve. MAIN RESULTS: In this review, we included 11 heterogeneous studies with a total number of 1569 MCI patients followed for conversion to dementia. Four studies assessed the role of baseline scores of the MMSE in conversion from MCI to all-cause dementia and eight studies assessed this test in conversion from MCI to Alzheimer´s disease dementia. Only one study provided information about the MMSE and conversion from MCI to vascular dementia. For conversion from MCI to dementia in general, the accuracy of baseline MMSE scores ranged from sensitivities of 23% to 76% and specificities from 40% to 94%. In relationship to conversion from MCI to Alzheimer's disease dementia, the accuracy of baseline MMSE scores ranged from sensitivities of 27% to 89% and specificities from 32% to 90%. Only one study provided information about conversion from MCI to vascular dementia, presenting a sensitivity of 36% and a specificity of 80% with an incidence of vascular dementia of 6.2%. Although we had planned to explore possible sources of heterogeneity, this was not undertaken due to the scarcity of studies included in our analysis. AUTHORS' CONCLUSIONS: Our review did not find evidence supporting a substantial role of MMSE as a stand-alone single-administration test in the identification of MCI patients who could develop dementia. Clinicians could prefer to request additional and extensive tests to be sure about the management of these patients. An important aspect to assess in future updates is if conversion to dementia from MCI stages could be predicted better by MMSE changes over time instead of single measurements. It is also important to assess if a set of tests, rather than an isolated one, may be more successful in predicting conversion from MCI to dementia.

摘要

相似文献

[1]
Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2015-3-5

[2]
Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2021-7-27

[3]
Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations.

Cochrane Database Syst Rev. 2016-1-13

[4]
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2017-3-22

[5]
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2017-11-22

[6]
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2017-11-22

[7]
Regional cerebral blood flow single photon emission computed tomography for detection of Frontotemporal dementia in people with suspected dementia.

Cochrane Database Syst Rev. 2015-6-23

[8]
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2015-1-28

[9]
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings.

Cochrane Database Syst Rev. 2016-11-21

[10]
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting.

Cochrane Database Syst Rev. 2015-3-10

引用本文的文献

[1]
Prospective Evaluation of Neurocognition in Patients Following Transcatheter Aortic Valve Replacement.

Struct Heart. 2025-4-4

[2]
Cerebral Hemodynamics as a Diagnostic Bridge Between Mild Cognitive Impairment and Late-Life Depression: A Multimodal Approach Using Transcranial Doppler and MRI.

Life (Basel). 2025-8-6

[3]
Stepwise approach to alzheimer's disease diagnosis in primary care using cognitive screening, risk factors, neuroimaging and plasma biomarkers.

Sci Rep. 2025-8-27

[4]
Depression and Hypomagnesemia as Independent and Synergistic Predictors of Cognitive Impairment in Older Adults Post-COVID-19: A Prospective Cohort Study.

Med Sci (Basel). 2025-8-6

[5]
Plasma and CSF Amyloid-β42 Predict Plasma Sortilin, Which Influences Cognitive Impairment via Mediation of Whole-Brain Volume: A 12-Month Longitudinal Study Across the Alzheimer's Disease Spectrum.

J Mol Neurosci. 2025-8-15

[6]
Can cognitive function tests discriminate between patients with glioma and healthy controls prior to treatment? A systematic review.

PLoS One. 2025-8-6

[7]
Cerebrospinal Fluid p‑Tau181/Amyloid Beta 42 Ratio Identifies Lymphatic-Venous Anastomosis Patients Who Respond to and Benefit from the Surgery for Relief of Cognitive Impairment with a Diagnostic Accuracy of 0.744.

ACS Omega. 2025-7-16

[8]
Serum moesin is associated with cognitive impairment and glucose fluctuations in patients with type 2 diabetes.

Diabetol Metab Syndr. 2025-7-29

[9]
Caregiving burdens of task time and task difficulty among paid and unpaid caregivers of persons living with dementia.

Front Public Health. 2025-7-9

[10]
Epidemiology of age-related macular degeneration among elderly in geriatric homes, East Cairo, Egypt.

BMC Public Health. 2025-7-18

本文引用的文献

[1]
Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Cochrane Database Syst Rev. 2021-2-10

[2]
Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting.

Cochrane Database Syst Rev. 2019-9-14

[3]
Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting.

Cochrane Database Syst Rev. 2018-2-22

[4]
Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias.

Cochrane Database Syst Rev. 2015-10-29

[5]
Handsearching did not yield additional unique FDG-PET diagnostic test accuracy studies compared with electronic searches: a preliminary investigation.

Res Synth Methods. 2012-6-14

[6]
Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting.

Cochrane Database Syst Rev. 2015-2-3

[7]
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2015-1-28

[8]
Diagnostic tools for alzheimer's disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviews.

BMC Neurol. 2014-9-24

[9]
Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies.

Cochrane Database Syst Rev. 2013-3-28

[10]
(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Cochrane Database Syst Rev. 2014-7-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索